Prostate cancer screening in Quebec: PSA test, for whom and when?

Prostate cancer is the most frequently diagnosed cancer in Canadian men, and the second most common cause of cancer death. Yet when detected at an early stage, treatment options are numerous and the prognosis is generally favorable. The PSA test - measuring prostate-specific antigen in the blood - is the most widely used screening tool, but its interpretation and indications are the subject of a nuanced medical debate that every concerned man should understand before deciding to use it. This article presents the PSA test, the populations for which a discussion with the doctor is particularly recommended, the limitations of this tool and what happens in the event of a high result.

The prostate and prostate cancer - what you need to know

The prostate is a small gland of the male reproductive system, located below the bladder, in front of the rectum. It plays a role in the production of seminal fluid. With age, the prostate naturally enlarges - this is known as benign prostatic hyperplasia (BPH), a very common, non-cancerous condition. Prostate cancer is a distinct entity from BPH, although the two can coexist and their symptoms sometimes overlap.

A cancer that is often silent in its early stages

In its early stages, prostate cancer usually causes no symptoms. Urinary signs - difficulty in urinating, weak stream, frequent nocturnal urges - are more associated with benign hyperplasia than with cancer itself, and their presence does not distinguish the two conditions. This is one of the reasons why screening by blood test is considered before any symptoms appear, as part of a proactive prevention approach.

Recognized risk factors

Several factors increase the risk of developing prostate cancer. Age is the main one: the vast majority of cases occur after the age of 50, and the risk increases progressively with advancing age. Family history also plays a significant role - having a father or brother with prostate cancer significantly increases personal risk. Ethnic origin is also a recognized factor: men of African or Caribbean descent statistically present a higher risk and a potentially worse prognosis, influencing screening recommendations in some guidelines.

The PSA test - what is it and how does it work?

PSA (prostate-specific antigen) is a protein produced by prostate cells and secreted in small quantities into the bloodstream. Its concentration in the blood can be measured by a simple blood test. An elevated PSA level can indicate a number of things - and therein lies the complexity of its interpretation.

What a high PSA can mean - and what it can't

An above-normal PSA level can be caused by prostate cancer - but also by benign prostatic hypertrophy, prostatitis (inflammation or infection of the prostate), recent sexual activity, a recent rectal examination, certain medications or even strenuous physical activity such as cycling. In other words, an elevated PSA is not synonymous with cancer. It indicates the need for further investigation. Conversely, a PSA in the normal range does not totally rule out the presence of cancer - some cancers develop with a low PSA.

Evolution of PSA over time - PSA velocity

Physicians are often interested not only in the absolute value of the PSA, but also in its evolution over time. A rapid increase in PSA from one year to the next - known as PSA velocity - can be more significant than a stable high value. This is why an early reference test has diagnostic value for future comparisons.

Free PSA and total PSA - a diagnostic nuance

PSA circulates in the blood in two forms: free and protein-bound. The ratio between free PSA and total PSA (free/total PSA) can help the physician refine his interpretation and estimate the likelihood that the elevated PSA is related to cancer rather than a benign cause. This additional information is sometimes used before deciding on further investigations.

For whom and when to discuss PSA testing - higher-risk populations

PSA screening for prostate cancer is not part of a systematic population-based screening program in Quebec - unlike, for example, colorectal cancer screening. The guidelines of Canadian learned societies, including the Canadian Urological Society, recommend an approach based on a shared decision between patient and physician, taking into account the individual risk profile, the potential benefits of screening and its limitations. This nuance is important: PSA testing is not recommended for all men over a certain age, but a discussion with the physician is strongly encouraged for certain groups.

Men with a family history of prostate cancer

Men who have a father, brother or son with prostate cancer - particularly if diagnosed before the age of 65 - are at increased risk. For this group, a discussion with the doctor about the advisability of a PSA test is generally recommended at an earlier age than for the general population. The doctor can help assess whether and when to start this follow-up.

Men of African or Caribbean descent

Epidemiological data indicate that men of sub-Saharan African or Caribbean descent are at higher risk of developing prostate cancer, and often at a more advanced stage at diagnosis. Earlier discussion of screening with the physician is recommended for this group in several guidelines.

Men aged 50 and over with no specific risk factors

For men with no family history or other risk factors, the discussion of PSA screening is generally broached around the age of 50 as part of a preventive medicine consultation. This is an opportunity for the doctor to present the benefits and uncertainties associated with screening - particularly the risk of overdiagnosis and overtreatment - so that the patient can make an informed choice.

What happens if the PSA is elevated? - steps in the investigation

An elevated PSA result does not automatically lead to a cancer diagnosis or treatment. It triggers a process of progressive investigation, each stage of which is decided by the doctor on the basis of the clinical picture.

Test repetition and contextualization

As a first step, the doctor may recommend repeating the PSA test after a set period of time, making sure that certain factors that could skew the results have been ruled out. If the result remains high, further tests may be considered.

Rectal examination - a complementary test

The digital rectal exam (DRE) is a clinical examination that allows the physician to assess the size, consistency and texture of the prostate via the rectal route. It can detect abnormalities that the PSA test alone does not, and is often performed in combination with PSA for a more complete assessment.

Prostate MRI and biopsy - the urologist's role

In the event of a worrying result, the doctor may refer the patient to a urologist for a specialized evaluation. A multiparametric MRI of the prostate is often performed prior to biopsy, to identify suspicious areas and guide sampling. A prostate biopsy, which involves removing small fragments of prostate tissue for anatomopathological analysis, is the examination that confirms or refutes the presence of cancer.

The concept of active surveillance - not all cancers require immediate treatment

An important point for patients to be aware of: not all prostate cancers require immediate treatment. Some low-risk cancers can be actively monitored - with regular PSA, digital rectal examination and periodic biopsy - without therapeutic intervention, to avoid the adverse effects of treatment for very slowly progressing cancers. This approach is recognized and regulated by urology oncology guidelines.

Access to prostate screening in medical clinics - without a family doctor

Many men in Quebec don't have a family doctor, which can be a barrier to accessing a discussion about prostate cancer screening. Yet this conversation deserves to take place - especially for men with risk factors. A medical consultation in an accessible medical clinic is a good way of broaching this subject and initiating a check-up if indicated.

Informed discussion and prescription of PSA test if appropriate

Clinique Omicron's professionals, available at its several points of service, can lead the discussion on prostate cancer screening, assess the patient's risk profile, prescribe the PSA test if the shared decision is in favor of screening, interpret the results and refer to a specialist if necessary. This approach is part of a structured preventive medicine framework, accessible without prior referral.

Men's health - global monitoring available

In addition to prostate screening, the medical team available at Clinique Omicron branches in Quebec offers men's health follow-up including periodic check-ups, cardiovascular health, STBBI screening and other aspects of men's health. A comprehensive approach allows us to look beyond emergencies and invest in long-term prevention.

FAQ - Prostate cancer screening in Quebec

Q : Is the PSA test covered by RAMQ?

A: Yes, the PSA test is a blood test covered by RAMQ when prescribed by a physician in an appropriate clinical context. Prescription by a physician is required to benefit from public coverage. In the context of medical follow-up or concerted screening, it is performed in the laboratory at no cost to the insured patient.

Q: Why are some doctors reluctant to recommend systematic PSA testing?

A: The main concern surrounding systematic PSA screening is the risk of overdiagnosis and overtreatment. Some prostate cancers detected by PSA would never have caused any significant health problems during the patient's lifetime - they progress very slowly and do not require aggressive treatment. However, prostate cancer treatments can have significant side effects (incontinence, erectile dysfunction). This is why current guidelines favor a shared-decision approach rather than automatic universal screening.

Q: Do I need to prepare before taking a PSA test?

A: Yes, certain precautions can help to obtain a more reliable result. The doctor may recommend avoiding sexual activity, strenuous exercise (especially cycling) or rectal examinations in the days leading up to the test, as these factors can temporarily raise PSA levels. These specific precautions will be specified by the professional prescribing the test.

Q: Does a normal PSA level guarantee the absence of cancer?

A: No. A PSA level within the normal range reduces the likelihood of significant prostate cancer, but does not totally rule it out. Some cancers develop with a low PSA, particularly in the early stages. This is one of the recognized limitations of the test. The PSA value must always be interpreted in the overall clinical context, taking into account the patient's age, prostate size and other factors.

Q: My father had prostate cancer - at what age should I talk to a doctor?

A: A first-degree family history (father, brother, son) increases the risk of prostate cancer and warrants discussion with a physician earlier than for the general population. Most guidelines suggest that men with a significant family history, especially if the cancer was diagnosed in a close relative before the age of 65, should start this discussion in their forties. The doctor can assess individual risk and propose a suitable follow-up schedule.

Medical consultation | Clinique Omicron